Nivolumab plus ipilimumab (NIVO plus IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial

被引：0

作者：

Escudier, Bernard

Mcdermott, David F.

Burotto, Mauricio

Choueiri, Toni K.

Hammers, Hans J.

Plimack, Elizabeth R.

Porta, Camillo

George, Saby

Powles, Thomas

Donskov, Frede

Atkins, Michael B.

Kollmannsberger, Christian K.

Grimm, Marc-Oliver

Tomita, Yoshihiko

Rini, Brian I.

Jiang, Ruiyun

Desilva, Heshani

Lee, Chung-Wei

Motzer, Robert J.

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA

[2] Gustave Roussy, Villejuif, France

[3] Beth Israel Deaconess Med Ctr, Dana Farber Harvard Canc Ctr, Boston, MA USA

[4] Bradford Hill Clin Res Ctr, Santiago, Chile

[5] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

[6] Harvard Med Sch, Boston, MA USA

[7] UT Southwestern, Kidney Canc Program, Dallas, TX USA

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Univ Pavia, Pavia, Italy

[10] Roswell Pk Canc Inst, Buffalo, NY USA

[11] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England

[12] Univ Hosp, Aarhus, Denmark

[13] British Columbia Canc Agcy, Vancouver, BC, Canada

[14] Jena Univ Hosp, Jena, Germany

[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan

[16] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.4_suppl.363

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：363 / 363

页数：1

共 50 条

[1] Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
Tannir, Nizar M.
Motzer, Robert J.
Albiges, Laurence
Plimack, Elizabeth R.
George, Saby
Powles, Thomas
Donskov, Frede
Rini, Brian, I
Grunwald, Viktor
Hammers, Hans J.
Choueiri, Toni K.
Gurney, Howard
Tykodi, Scott S.
Porta, Camillo
Burotto, Mauricio
Tomita, Yoshihiko
Lee, Chung-Wei
Tang, Chad
McDermott, David F.
McKay, Rana R.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[2] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Tannir, Nizar M.
Frontera, Osvaldo Aren
Hammers, Hans J.
Carducci, Michael Anthony
McDermott, David F.
Salman, Pamela
Escudier, Bernard
Beuselinck, Benoit
Amin, Asim
Porta, Camillo
George, Saby
Bracarda, Sergio
Tykodi, Scott S.
Powles, Thomas
Rini, Brian I.
Tomita, Yoshihiko
McHenry, M. Brent
Mekan, Sabeen Fatima
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[3] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Albiges, Laurence
Tannir, Nizar M.
Burotto, Mauricio
McDermott, David
Plimack, Elizabeth R.
Barthelemy, Philippe
Porta, Camillo
Powles, Thomas
Donskov, Frede
George, Saby
Kollmannsberger, Christian K.
Gurney, Howard
Grimm, Marc-Oliver
Tomita, Yoshihiko
Castellano, Daniel
Rini, Brian, I
Choueiri, Toni K.
Saggi, Shruti Shally
McHenry, M. Brent
Motzer, Robert J.
ESMO OPEN, 2020, 5 (06)
[4] Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
Atkins, Michael B.
Escudier, Bernard
Mcdermott, David F.
Burotto, Mauricio
Choueiri, Toni K.
Hammers, Hans J.
Plimack, Elizabeth R.
Porta, Camillo
George, Saby
Powles, Thomas
Donskov, Frede
Kollmannsberger, Christian K.
Grimm, Marc-Oliver
Tomita, Yoshihiko
Rini, Brian, I
Jiang, Ruiyun
Federov, Viktor
Lee, Chung-Wei
Desilva, Heshani
Tannir, Nizar M.
Motzer, Robert J.
ONCOLOGIST, 2024, 29 : S17 - S18
[5] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
Motzer, R. J.
Tannir, N. M.
McDermott, D. F.
Burotto, M.
Choueiri, T. K.
Hammers, H. J.
Plimack, E. R.
Porta, C. G.
George, S.
Powles, T. B.
Donskov, F.
Gurney, H.
Kollmannsberger, C. K.
Grimm, M-O.
Tomita, Y.
Rini, B. I.
McHenry, M. B.
Lee, C-W.
Escudier, B.
ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
[6] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
Grimm, M. -O.
Tannir, N.
McDermott, D.
Escudier, B.
Hammers, H.
Aren Frontera, O.
Plimack, E.
Barthelemy, P.
Neiman, V.
George, S.
Porta, C.
Powles, T.
Donskov, F.
Amin, A.
Tykodi, S.
Tomita, Y.
Rini, B.
McHenry, M. B.
Saggi, S. S.
Motzer, R.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
[7] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[8] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Albiges, L.
Tannir, N.
Burotto, M.
McDermott, D. F.
Plimack, E. R.
Barthelemy, P.
Porta, C. G.
Powles, T. B.
Donskov, F.
George, S.
Kollmannsberger, C.
Gurney, H.
Grimm, M-O.
Tomita, Y.
Castellano Gauna, D.
Rini, B. I.
Choueiri, T. K.
Saggi, S. S.
McHenry, M. B.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
[9] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
Motzer, Robert J.
Choueiri, Toni K.
McDermott, David F.
Powles, Thomas
Yao, Jin
Ammar, Ron
Papillon-Cavanagh, Simon
Saggi, Shruti S.
McHenry, Brent M.
Ross-Macdonald, Petra
Wind-Rotolo, Megan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] EXTRACELLULAR MATRIX (ECM) BIOMARKERS ARE ELEVATED IN ADVANCED RENAL CELL CARCINOMA (ARCC) AND PREDICTIVE OF RESPONSE TO NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI): ANALYSIS FROM CHECKMATE 214
Gupta, Saurabh
Han, Celine
Dwivedi, Bhakti
Li, Jun
Karsdal, Morten
Motzer, Robert
Willumsen, Nicholas
McDermott, David
Choueiri, Toni
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A581 - A581

← 1 2 3 4 5 →